What is William Blair’s Estimate for CNTX Q2 Earnings?

Context Therapeutics Inc. (NASDAQ:CNTX) – William Blair issued their Q2 2026 earnings per share estimates for Context Therapeutics in a report issued on Tuesday, April 29th. William Blair analyst M. Phipps anticipates that the company will earn ($0.09) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.51) per share. William Blair also issued estimates for Context Therapeutics’ Q4 2026 earnings at ($0.07) EPS.

A number of other analysts have also weighed in on the company. JMP Securities initiated coverage on Context Therapeutics in a research note on Wednesday, January 8th. They set an “outperform” rating and a $4.00 price objective for the company. D. Boral Capital reissued a “buy” rating and issued a $9.00 price target on shares of Context Therapeutics in a report on Tuesday. HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Context Therapeutics in a report on Friday, March 21st. Finally, Citizens Jmp upgraded Context Therapeutics to a “strong-buy” rating in a report on Wednesday, January 8th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Context Therapeutics has an average rating of “Buy” and an average price target of $6.17.

Context Therapeutics Price Performance

Shares of CNTX opened at $0.86 on Thursday. The firm has a market cap of $77.37 million, a P/E ratio of -0.95 and a beta of 2.18. Context Therapeutics has a 1 year low of $0.55 and a 1 year high of $2.75. The stock has a 50 day simple moving average of $0.78 and a two-hundred day simple moving average of $1.18.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01.

Institutional Trading of Context Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp increased its holdings in Context Therapeutics by 21.5% in the 3rd quarter. State Street Corp now owns 111,907 shares of the company’s stock worth $219,000 after acquiring an additional 19,800 shares in the last quarter. Clear Harbor Asset Management LLC boosted its position in shares of Context Therapeutics by 60.6% in the fourth quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock worth $61,000 after purchasing an additional 21,804 shares during the period. Jane Street Group LLC bought a new position in shares of Context Therapeutics in the fourth quarter worth approximately $29,000. Citadel Advisors LLC purchased a new stake in shares of Context Therapeutics in the fourth quarter worth $31,000. Finally, Millennium Management LLC raised its position in shares of Context Therapeutics by 24.2% during the 4th quarter. Millennium Management LLC now owns 178,718 shares of the company’s stock valued at $188,000 after purchasing an additional 34,835 shares during the period. Hedge funds and other institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.